David Suhy
genetic phamaceutical
All India Alcohol Based Industries Development Association Ashok Chem-Pharma International
Australia
Biography
David oversees and leads the development of all of Benitec’s therapeutic programs controlling the scientific direction and budget as well as oversees implementation of new technologies. Benitec's technology combines the application of RNA interference with gene therapy delivery approaches. This enables the creation of RNAi-based therapeutics that have the potential to treat human diseases with a single administration of the drug. As one of the inventors of TT-033, he directed development of the TT-03x series of compounds which target the Hepatitis C virus (HCV), from the drawing board through completion of a Phase I/IIa clinical study.
Research Interest
creation of RNAi-based therapeutics that have the potential to treat human diseases .
